Caribou Biosciences (CRBU) AI Stock Analysis

• Market Cap: $103.24M
• Dividend Yield: N/A
• Average Volume (3M): 1.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.33
• Revenue Growth: -70.31%
• EPS Growth: -11.68%
• Country: US
• Employees: 147
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -0.43
• Shares Outstanding: 93,004,600
• 10 Day Avg. Volume: 1,316,514
• 30 Day Avg. Volume: 1,033,475
• PEG Ratio: 0.26
• Price to Book (P/B): 1.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.03
• Enterprise Value/Market Cap: 3.86
• Enterprise Value/Revenue: 6.18
• Enterprise Value/Gross Profit: 50.63
• Enterprise Value/Ebitda: -0.64
• 1Y Price Target: $5.20
• Price Target Upside: 368.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 46 Neutral
• Price Target: $1.00 ▼(-9.91%Downside)

Caribou Biosciences' score is primarily impacted by its weak financial performance, marked by declining revenues and significant losses. Technical analysis provides a slightly positive outlook, though valuation remains a concern with a negative P/E ratio. The absence of dividend yield further diminishes investment appeal.

Positive Factors

Financial Position

The company ended the period with $212.5 million in cash and equivalents, expected to fund upcoming developments.

Strategic Focus

Caribou announced a strategic reprioritization to focus on oncology programs for CB-010 in large B cell lymphoma (LBCL) and CB-011 in multiple myeloma (MM) with a workforce (~32%) and cost reduction.

Negative Factors

Clinical Risk

Risks include negative clinical results with the company's lead assets, delays in advancing these candidates into registrational programs, and failure to achieve favorable clinical results with other pipeline candidates.

Pipeline Discontinuation

The discontinuation of CB-010 in lupus, CB-012 in AML, and preclinical research does reduce the value from the pipeline.

Caribou Biosciences Business Overview & Revenue Model

Company Description

Caribou Biosciences, Inc. (CRBU) is a biotechnology company that pioneers the development of genome editing technologies. The company operates in the healthcare sector, primarily focusing on the research and development of CRISPR-based genome editing solutions. Caribou Biosciences aims to enhance the precision and efficiency of genome editing for therapeutic applications, with a strong emphasis on improving patient outcomes in the treatment of various genetic disorders and diseases.

How the Company Makes Money

Caribou Biosciences generates revenue primarily through partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve joint research and development efforts or the licensing of Caribou's proprietary CRISPR technology. Additionally, the company may receive milestone payments and royalties associated with the successful development and commercialization of products resulting from these collaborations. Caribou's revenue model is significantly influenced by its ability to advance its technology platform and establish strategic partnerships to leverage its genome editing capabilities in therapeutic settings.

Caribou Biosciences Financial Statement Overview

Summary

Caribou Biosciences is facing challenges with declining revenues, substantial operational losses, and negative cash flows, overshadowing its strong equity position and low leverage ratio. The company needs to improve revenue growth and operational efficiency for better financial health.

Income Statement

Caribou Biosciences shows declining revenue, with the TTM (Trailing-Twelve-Months) revenue at $9.918 million compared to $34.477 million the previous year, indicating a significant drop. The gross profit margin for TTM is approximately 79.41%, suggesting high efficiency in cost management relative to revenue. However, the company is struggling with significant losses as evidenced by the negative net profit margin and EBIT margin, with a TTM net income of -$147.862 million. These figures reflect challenges in scaling revenue while controlling operational costs.

Balance Sheet

The company maintains a solid equity base with a stockholders' equity of $217.222 million in the TTM period. The debt-to-equity ratio stands at 0.12, indicating low leverage and a conservative capital structure. However, the ROE is negative due to the company's net losses, impacting profitability. The equity ratio is relatively strong, suggesting a healthy buffer of equity relative to total assets. Despite the strengths in capital structure, consistent losses pose a risk to long-term financial stability.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, with TTM free cash flow at -$142.196 million, indicating cash strain from operations. The ratio of operating cash flow to net income is less than 1, highlighting inefficient cash conversion. Though the company has substantial cash reserves, the negative cash flow trends point to potential liquidity issues if losses persist without external financing or revenue improvement.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.92M	9.99M	34.48M	13.85M	9.60M	12.36M
	Gross Profit
7.88M	6.07M	-77.60M	10.21M	8.61M	-22.06M
	EBIT
-163.53M	-166.62M	-116.06M	-106.40M	-66.98M	-36.12M
	EBITDA
-160.32M	-166.62M	-112.53M	-104.78M	-66.00M	-35.21M
	Net Income Common Stockholders
-147.86M	-149.10M	-102.07M	-99.42M	-66.92M	-34.31M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
208.47M	209.54M	328.83M	317.04M	413.51M	15.95M
	Total Assets
273.66M	313.31M	432.21M	373.76M	442.36M	36.05M
	Total Debt
26.22M	26.49M	27.11M	27.75M	259.00K	1.58M
	Net Debt
-3.19M	10.19M	-24.05M	-30.59M	-240.16M	-14.38M
	Total Liabilities
56.43M	60.36M	63.81M	72.89M	54.53M	59.48M
	Stockholders Equity
217.22M	252.95M	368.40M	300.87M	387.82M	-23.44M
Cash Flow		Free Cash Flow
-142.20M	-143.08M	-104.90M	-98.02M	-35.64M	-34.53M
	Operating Cash Flow
-137.72M	-138.20M	-93.29M	-90.97M	-32.52M	-33.22M
	Investing Cash Flow
113.03M	86.61M	-68.18M	-93.25M	-176.40M	6.36M
	Financing Cash Flow
4.71M	16.72M	154.30M	2.13M	433.43M	1.74M

Caribou Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBU, the sentiment is Neutral. The current price of 1.11 is above the 20-day moving average (MA) of 1.11, above the 50-day MA of 0.93, and below the 200-day MA of 1.51, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 53.29 is Neutral, neither overbought nor oversold. The STOCH value of 52.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRBU.

Caribou Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EDIT	60 Neutral	$182.49M	―	-140.82%	―	-48.37%	-44.70%
MGNX	57 Neutral	$97.79M	―	-60.25%	―	255.31%	-141.39%
VXRT	54 Neutral	$122.60M	―	-114.74%	―	433.43%	49.04%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
CRBU	46 Neutral	$103.24M	―	-52.76%	―	-70.31%	-11.68%
ZURA	43 Neutral	$75.49M	―	-62.34%	―	―	86.65%
ELTX	30 Underperform	$121.58M	―	-744.59%	―	―	27.65%

Caribou Biosciences Corporate Events

Caribou Biosciences Confirms Director Elections and Auditor

On June 12, 2025, Caribou Biosciences, Inc. held its annual meeting of stockholders, where several key proposals were voted on. The election of two Class I directors, Scott Braunstein, M.D. and Ran Zheng, M.S., was confirmed, and the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, stockholders approved an amendment to the company’s certificate of incorporation to allow a reverse stock split and the potential adjournment of the annual meeting if necessary, although the latter was not needed as there was a quorum and sufficient votes for the proposals.

The most recent analyst rating on (CRBU) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.